Patric Stenberg (born 1970) is one of the co-founders of Gesynta Pharma. He holds a PhD in Pharmaceutics from Uppsala University. Patric has more than 20 years of experience from positions as CEO, Chief Scientific Officer, business development manager and pharmaceutical R&D scientist within the life science industry, ranging from small virtual organizations to global pharma companies.
Board Director of Capensa AB
Charlotte Edenius (born 1958), M.D, Ph.D., is one of the co-founders of Gesynta Pharma. Charlotte has more than 25 years of experience from positions within the life science industry with experience from all phases of drug development as well as business development including successful partnering and licensing. Her experience spans from AstraZeneca to biotech companies including senior management positions as EVP R&D, Medivir AB, SVP Research, Orexo AB, and CSO, Biolipox AB. Charlotte has also served in non-executive board positions in several private and public pharma companies, including Karolinska Development AB.
Board Director of Kancera AB (publ)
Chairman of the Board and CEO of Allmora Life Science AB
Gunilla Ekström (born 1958) is one of the co-founders of Gesynta Pharma. She holds an MD, PhD and associate professorship from Karolinska Institutet. Gunilla has more than 30 years of experience from the pharmaceutical industry including all stages of drug development, from discovery to registration. Her previous roles include senior management positions at AstraZeneca, Orexo and Karolinska Development. Further, she has served as CEO in several smaller companies. Gunilla has also served as non-executive director in several pharma companies, such as NovaSAID.
Board Director of Corline Biomedical AB, Disruptive Pharma AB, Emplicure AB, Gabather AB and Strike Pharma AB
Michaela Gertz (born 1981) holds an MSc in Business and Economics from Uppsala University. She has more than 15 years of experience from positions as CFO, Investor Relations Manager and Head of Investor Relations & Financing in several life science companies listed on Nasdaq Stockholm.
Board Director of Codemill AB (publ)
Board Director and CEO of Gertz Consulting AB
Göran Tornling (born 1947) holds an MD, PhD, and an associate professorship in respiratory medicine at the Karolinska Institutet. Göran has more than 20 years of experience from all phases of drug development including leading positions at AstraZeneca, Biolipox and Orexo. Göran is the author of more than 100 articles and book chapters.
Board Director of AcuCort AB
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.
Raynaud’s phenomenon affects most systemic sclerosis patients. It is often the first sign of the disease.
Half of systemic sclerosis patients develop difficult-to-heal digital ulcers, hampering many everyday activities.
Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.